Literature DB >> 10672628

Sub-chronic inhibition of nitric-oxide synthesis modifies haloperidol-induced catalepsy and the number of NADPH-diaphorase neurons in mice.

E A Del Bel1, F S Guimarães.   

Abstract

RATIONALE: NG-nitro-L-arginine (L-NOARG), an inhibitor of nitric-oxide synthase (NOS), induces catalepsy in mice. This effect undergoes rapid tolerance, showing a significant decrease after 2 days of sub-chronic L-NOARG treatment. Nitric oxide (NO) has been shown to influence dopaminergic neurotransmission in the striatum. Neuroleptic drugs such as haloperidol, which block dopamine receptors, also cause catalepsy in rodents.
OBJECTIVES: To investigate the effects of subchronic L-NOARG treatment in haloperidol-induced catalepsy and the number of NOS neurons in areas related to motor control.
METHODS: Male albino Swiss mice were treated sub-chronically (twice a day for 4 days) with L-NOARG (40 mg/kg i.p.) or haloperidol (1 mg/kg i.p.). Catalepsy was evaluated at the beginning and the end of the treatments. Reduced nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d) histochemistry was also employed to visualize NOS as an index of enzyme expression in mice brain regions related to motor control.
RESULTS: L-NOARG sub-chronic administration produced tolerance of L-NOARG and of haloperidol-induced catalepsy. It also induced an increase in the number of NADPH-d-positive cells in the dorsal part of the caudate and accumbens nuclei compared with haloperidol and in the pedunculopontine tegmental nucleus compared with saline. In contrast, there was a decrease in NADPH-d neuron number in the substantia nigra, pars compacta in both haloperidol-treated and L-NOARG-treated animals.
CONCLUSIONS: The results give further support to the hypothesis that NO plays a role in motor behavior control and suggest that it may take part in the synaptic changes produced by antipsychotic treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10672628     DOI: 10.1007/s002130050003

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  7 in total

Review 1.  Role of nitric oxide on motor behavior.

Authors:  E A Del Bel; F S Guimarães; M Bermúdez-Echeverry; M Z Gomes; A Schiaveto-de-souza; F E Padovan-Neto; V Tumas; A P Barion-Cavalcanti; M Lazzarini; L P Nucci-da-Silva; D de Paula-Souza
Journal:  Cell Mol Neurobiol       Date:  2005-03       Impact factor: 5.046

2.  Combined treatment of ascorbic acid or alpha-tocopherol with dopamine receptor antagonist or nitric oxide synthase inhibitor potentiates cataleptic effect in mice.

Authors:  M Lazzarini; C Salum; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

3.  Dopamine and nitric oxide interaction on the modulation of prepulse inhibition of the acoustic startle response in the Wistar rat.

Authors:  C Salum; F S Guimarães; M L Brandão; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2006-01-10       Impact factor: 4.530

4.  Early suppression of striatal cyclic GMP may predetermine the induction and severity of chronic haloperidol-induced vacous chewing movements.

Authors:  A M Bester; B H Harvey
Journal:  Metab Brain Dis       Date:  2000-12       Impact factor: 3.584

5.  Long-term CB₁ receptor blockade enhances vulnerability to anxiogenic-like effects of cannabinoids.

Authors:  Simone Tambaro; Maria Lauda Tomasi; Marco Bortolato
Journal:  Neuropharmacology       Date:  2013-02-24       Impact factor: 5.250

6.  Nitric Oxide-Soluble Guanylyl Cyclase-Cyclic GMP Signaling in the Striatum: New Targets for the Treatment of Parkinson's Disease?

Authors:  Anthony R West; Kuei Y Tseng
Journal:  Front Syst Neurosci       Date:  2011-06-30

7.  Intracerebroventricular administration of nitric oxide-sensitive guanylyl cyclase inhibitors induces catalepsy in mice.

Authors:  M B Echeverry; M L Salgado; F R Ferreira; C A da-Silva; E A Del Bel
Journal:  Psychopharmacology (Berl)       Date:  2007-06-26       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.